SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive mucoadhesion data for its intranasal Naloxone program, sparking excitement about its potential as a multi-day runner. Community discussions revolve around the significance of the manufacturing milestone and superior data, while some traders are wary of potential dilution given the company's history and low float. The stock is also gaining attention within the context of other low-float Israeli stocks experiencing significant moves.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the quantum computing sector garners attention, with discussions focusing on its superconducting QPU systems and potential for scalability compared to other quantum computing approaches. Community members debate the company's valuation relative to its revenue and the competitive landscape, while also discussing potential catalysts and trading strategies involving options. Some are optimistic about Rigetti's technology and long-term potential, while others express skepticism, citing concerns about profitability and competition from larger companies.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders discuss its potential for institutional adoption and retail activity, specifically meme coins. Community members are analyzing entry points and debating its ability to outperform other cryptos, while some express concern over recent price drops. Bullish sentiment revolves around potential rallies and strong community support.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending due to its recent earnings report, which showed record revenue and profit, sparking discussions about its undervaluation relative to competitors like HOOD. The community is highlighting the company's strong growth in global client assets and its potential for significant price appreciation, drawing comparisons to HOOD's earlier run-up.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about a potential acquisition of Warner Bros. Discovery, with many debating whether the deal would be beneficial. Community discussions revolve around potential price targets and technical analysis, while some express concerns about the company's recent performance and programming decisions. The possibility of a bidding war with other major players like Comcast and Paramount Skydance is also fueling the conversation.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending amid speculation and excitement around the robotics sector, driven by potential government support and company-specific developments like overnight trading highs and high trading volumes. Community members are actively discussing potential short squeezes and comparing SERV to other robotics plays, anticipating further gains and focusing on the company's growth prospects with its DoorDash partnership. Some see a buying opportunity, while others are wary, pointing to past volatility and dilution.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending following the release of its Q3 earnings, which beat analyst expectations and showed profitability. The community is actively discussing the company's growth, partnerships, and potential for a continued uptrend, while also debating its valuation relative to peers and the impact of short positions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the revival of OG memes on the Solana blockchain. Community members emphasize consistent engagement and building a strong culture, expressing conviction that $RAGE represents more than just a coin. Discussions highlight the importance of community over charts, with members actively working towards broader recognition and adoption.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as investors react to the company's announcement of a new U.S. Government Business Unit and recent analyst coverage with an outperform rating. Community discussions revolve around potential government contracts and the company's prospects within the quantum computing sector.  Despite being unprofitable, some investors are drawn to QBTS as a pure-laser computing play and a potential beneficiary of growing AI energy demands.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending amid mixed sentiment following recent trial setbacks and shareholder lawsuits, though analysts see potential upside and key readouts are expected in the coming quarters. Community members are weighing the risks against the potential for a buyout, drawing comparisons to other biotech successes, and closely watching the upcoming FDA meeting for clarity. Discussions also focus on technical analyses, potential market size, and institutional investment activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Misses Estimates By $0.07 EPS

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts...

Atea Pharmaceuticals Earnings Preview

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.
read more...

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with...

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400...

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

Q1 2024 Earnings Forecast for Atea Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report)  Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research note...

Leerink Partnrs Research Analysts Decrease Earnings Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR  Free Report)  Analysts at Leerink Partnrs reduced their FY2023 earnings per share (EPS) estimates for Atea Pharmaceuticals in a report released...

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Current Price	$3.09
Prev Close	$3.00
Open	$3.01
Dividend Yield	0.00%
50-Day Moving Average	$3.11
Beta	0.85
Avg. Volume	428,923.37
PE Ratio	-1.74

52-Week High	$4.02
52-Week Low	$2.46
Market Capitalization	$234.38M
EPS (Annual)	-$2.00
Price to Book	0.76
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AVIR
Atea Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVIR News

AVIRAtea Pharmaceuticals Inc